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Abstract
Mutations in PRKAG2 gene that regulates the γ2 subunit of the adenosine monophosphate (AMP)
dependent protein kinase have been associated with the development of atrioventricular (AV) accessory
pathways, cardiac hypertrophy, and conduction system abnormalities. These patients can potentially be
misdiagnosed as hypertrophic cardiomyopathy (HOCM) and/or Wolf-Parkinson White (WPW) syndrome
due to similar clinical phenotype. Early recognition of this disease entity is very important as ablation of
suspected accessory pathways is not effective and the natural history of the disease is very different from
HOCM and WPW syndrome.
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INTRODUCTION
We describe an adolescent female affected by PRKAG-2 gene mutation misdiagnosed to have hypertrophic
cardiomyopathy (HOCM) and/or Wolf-Parkinson White (WPW) syndrome. Despite ablation of the
suspected accessory pathways, she experienced life-threatening arrhythmias. We aim to reiterate the
importance of early recognition of this entity and possible placement of implantable cardioverter-
defibrillator (ICD) early in the course of management to prevent catastrophic arrhythmias and possible
sudden cardiac death.
CASE REPORT
A 14-year-old girl presented with sudden onset of pre-excited atrial fibrillation with a rapid ventricular
response. She was hemodynamically stable and was treated with a procainamide bolus, which converted
the rhythm to sinus. She was then transferred to our facility for further work-up and management. At
presentation, she was alert and oriented with no distress. She had a heart rate (HR) of 71 bpm with a
normal respiratory rate, blood pressure, physical exam, complete blood count (CBC), and basic metabolic
profile.
She was believed to have hypertrophic cardiomyopathy and WPW syndrome with multiple accessory
pathways first diagnosed 4 years prior to this presentation. At that time, she underwent successful ablation
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of a two rapidly conducting accessory pathways in the right antero-lateral and left lateral atrioventricular
(AV) groove. She had a third mid-septal to antero-septal pathway; however, this pathway was not ablated
at the time, due to the relative proximity to AV node, the limited antegrade conduction properties, and the
lack of retrograde conduction. She was treated with atenolol. One week prior to current admission, she had
a syncopal event while doing her normal activities and a Holter performed at that time demonstrated
tachycardia. The type of tachycardia however was not specified in the records and the tracings were not
available for review.
The patient had a strong family history of heart disease. Her mother had WPW syndrome and hypertrophic
cardiomyopathy (HCM) and had atrial fibrillation at 12 years of age. She subsequently had placement of
an ICD. Her maternal uncle, who was previously healthy, died suddenly at the age of 32 years. Also, her
maternal cousin had WPW syndrome.
Electrocardiography (ECG) at the time of presentation to our hospital showed evidence of ventricular pre-
excitation [Figure 1]. There was concentric left ventricular hypertrophy with left ventricular diastolic
septal thickness of 1.38 cm (z score 3.82) [Figure 2], which was comparable to her previous
echocardiogram 4 year earlier. Her anatomy was otherwise normal with normal systolic ventricular
function. Considering the past history of WPW and evidence of pre-excitation on ECG, she underwent
electro-physiological testing. Surprisingly, two new accessory pathways (right postero-septal, right lateral)
were mapped besides the midseptal pathway which was present at the first electrophysiological testing.
Both right-sided pathways were successfully ablated. The midseptal pathway demonstrated delayed
elimination (10-15 seconds) with application of radiofrequency energy, though this was soon followed by
accelerated junctional rhythm requiring termination of the lesion. This accessory pathway, as noted
previously, had limited antegrade conduction and no retrograde conduction.
Her post-operative course was remarkable for the development of a variety of AV conduction findings.
Post ablation ECG demonstrated normal AV node conduction with persistence of pre-excitation, though a
different delta wave pattern [Figure 3]. On post-operative day 4, she developed sinus rhythm with first-
degree AV block and no evidence of ventricular pre-excitation. Two days later, this progressed to compete
AV block. The following day, her AV node conduction returned, though there was still no evidence of pre-
excitation. On post-operative day 9, ventricular pre-excitation was once again evident. She underwent
implantation of a dual chamber ICD in view of the episode of high-grade AV block and history of syncope
in the setting of hypertrophic cardiomyopathy [Figure 4].
Genetic testing demonstrated the patient to be heterozygous in the PRKAG2 gene coding for a missense
mutation defined as c.1589 A > G. This gene is predicted to result in amino acid substitution p. His530Arg.
The c.1589 A > G variant has not been observed in 5,700 healthy individuals sequenced in the NHLB1
exon sequencing project and 1,000 genomes project. Genetic counseling was provided to the patient and
her parents. Genetic testing for the mutation was also advised for her mother and affected relatives.
DISCUSSION
Accessory AV connections are present between the atria and ventricles where normally no muscle exists.
Few patients with accessory AV connections have WPW syndrome, an arrhythmogenic defect
characterized by a normal conduction system and one or multiple AV connections that result in ventricular
pre-excitation and predispose to re-entrant supraventricular tachycardia (SVT).[1] The majority of WPW
syndrome patients present with no other cardiac abnormalities.[2] However, some families have WPW
syndrome as a part of a more extensive cardiac disease, or as a multisystem syndrome.[3,4,5]
HCM is one of the most common inherited cardiac disorder with a prevalence of 1 in 500. It is diagnosed
clinically by the presence of unexplained left ventricular hypertrophy, myocyte hypertrophy, and myofiber
disarray on histopathological evaluation.[6] It is usually considered a disease of the cardiac sarcomere
although sarcomeric protein mutations are identified only in about two-third of patients.[7]
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In some affected families, HCM is associated with ventricular pre-excitation, a high incidence of
arrhythmia and sudden cardiac death. Affected individuals sometimes exhibit high degree of AV block,
which usually is an uncommon manifestation of WPW or HCM. Mac Ree et al.,[8] in 1995 identified the
chromosome region 7q3 as a locus responsible for HCM associated with electrophysiological pre-
excitation or WPW syndrome. Subsequently, Gollob et al.,[3] in 2001 performed genetic linkage analysis,
followed by candidate gene approach to identify the PRKAG2 gene, a possible causative gene in patients
with HCM and WPW. Since the original report, several mutations have been identified, all these have been
missense mutations in the PRKAG2 gene.[9]
PRKAG2 syndrome is a rare autosomal dominant essentially heart-specific non-lysosomal glycogenosis.
Typically, affected patients present in late adolescence, have evidence of pre-excitation on ECG with
frequent paroxysms of supra-ventricular tachycardia and frequently progress to high-grade conduction
system disease requiring placement of a pacemaker device by fourth to fifth decade of life.[10] A
significant proportion of these patients develop mild to severe cardiac hypertrophy that progresses to
dilated cardiomyopathy.
It is notable that the arrhythmogenic nature of the disease is not caused due to a defect in ion channel or a
structural protein. Rather, PRKAG2 gene encodes the γ 2 regulatory subunit of adenosine monophosphate
(AMP)-activated protein kinase (AMPK) and thus it is a disease of cardiac metabolism. AMPK enzyme
activity serves a critical role in regulating cellular glucose and fatty acid metabolic pathways. In situations
of increased cellular energy demand in muscle, AMPK activation promotes adenosine triphosphate (ATP)
repletion by facilitating cellular glucose uptake and oxidative metabolism.[11] A perturbation in the
exquisite regulation of these metabolic pathways, as caused by mutations in the regulatory subunit of
AMPK, leads to a derangement in cardiac metabolism, giving rise to the profound cardiac phenotypes
described.
Ideally, the diverse clinical features of the PRKAG2 cardiac syndrome should be explained by a single
dominant cellular abnormality resulting from altered AMPK activity. The findings of Wolf et al.,[12]
provide strong evidence that excessive cellular glycogen content alone is a unifying mechanism of disease
pathogenesis for the variable phenotypes manifested in affected patients. The degree of cardiac
hypertrophy observed on imaging will be dependent on the extent of myocyte enlargement secondary to
glycogen accumulation. Similar to our patient, this is often diagnosed as hypertrophic cardiomyopathy on
echocardiography despite widely differing pathogenesis. Why some patients demonstrate extraordinary
hypertrophy and other affected members of the same family do not remains an enigma. It most likely
reflects a role of functional polymorphisms of other genes influencing cellular glucose metabolism. The
presence of ventricular pre-excitation is also the result of cellular enlargement due to excessive glycogen
content, resulting in the disruption of the normal development of the annulus fibrosus, as observed by Wolf
et al. The end result is ECG evidence for ventricular pre-excitation and, in the context of frequent
supraventricular arrhythmias, it might be erroneously labeled as WPW syndrome. As the patients age,
myocytes gradually accumulate more and more glycogen. These swollen myocytes conduct impulses from
atria to ventricles at various locations and are diagnosed as aberrant AV conduction pathways on
electrophysiological studies. In a child with idiopathic cardiac hypertrophy and presumed sporadic
cardiomyopathy, who was negative for mutations in nine of the known HCM genes, Morita et al.,[13]
identified heterozygosity for a missense mutation in the PRKAG2 gene (H530R; 602743.0009). The
mutation was not found in unrelated individuals matched by ancestral origin or in more than 1,000 control
chromosomes.
CONCLUSION
We describe the clinical case of an adolescent girl who had the typical presentation of the disease with the
genetic mutation in PRKAG2 gene. Even a patient with the classical phenotype may be missed because of
lack of physician awareness. Diagnosis in our patient was not considered for a few years and she
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experienced life-threatening arrhythmias. We stress the importance of early recognition of this entity as
these patients have a progressive disease. Subjecting these patients to ablation procedures is fruitless as the
aberrant conduction is due to swollen glycogen accumulated cardiac myocytes and not due to accessory
pathways. Future possibility for gene therapy for this serious illness needs to be explored in detail. Until
such disease reversing therapies are explored, these patients should be considered for early ICD placement
as therapy for life-threatening arrhythmias and to prevent catastrophic events and sudden cardiac death.
Footnotes
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Figure 1
Baseline electrocardiography (ECG) done at presentation to hospital showing pre-excitation characteristic of antegrade
conduction through atrioventricular (AV) node and the accessory pathway. Note the short PR interval and slurred upstroke
of QRS complex
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Figure 2
Echocardiogram done at time of presentation showing concentric ventricular hypertrophy in apical view (a) and
parasternal long axis view (b)
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Figure 3
Electrocardiography (ECG) post ablation day 1 showed persistent pre-excitation, though a different pattern as compared
to her baseline
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Figure 4
Electrocardiography (ECG) after implantable cardioverter-defibrillator (ICD) implantation (post ablation day 6) showing
complete AV block and ventricular paced rhythm
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